We have previously demonstrated that rat aortic allografts from the DA (RT1*) to the WF (RT1") strain develop chronic arteriosclerotic changes in the vascular wall after a short spontaneously reversible acute rejection episode. These changes, which are lacking in syngeneic DA-to-DA control grafts, are virtually identical with those observed in human allografts during chronic rejection. In this study we have investigated whether eicosanoids are involved in the generation of arteriosclerotic changes. Incubation of aortic wall rings in vitro and immunochemical assays demonstrated that the arteriosclerotic allografts synthesize significantly more thromboxane B 2 (TxB^) but not 6-ketoprostaglandin F l o (6-keto-PGF,,,) or leukotriene B 4 . The increased synthesis of TxBj in the allografts persisted for at least 5 months after transplantation. Separate incubation of the two major components of the vascular wall, after microdissectioa of the intima and (media phis) adventitia, demonstrated that most of the synthesis of TxB? during chronic rejection was due to the outer layer of aorta, presumably the inflammatory cells of the adventitia. In contrast, most of the 6-keto-PGF,» was synthesized by the inner layer of the aorta, presumably the endothelial cells and the smooth muscle cells of the intima. Administration of 1 ing • kg" 1 • day" 1 of a specific TxA 2 receptor inhibitor, GR32191B, to the recipient rat reduced the proliferative response of inflammatory cells in the adventitia by 30%, as detected by in vivo tritiated-thymidine ( 3 H-TdR) labeling and autoradiography, but did not reduce the proUferatlve response of smooth muscle cells in the media and intima. The drug also delayed the intlmal thickening and the generation of aUograft arteriosclerosis by 1 month but was unable to inhibit it indefinitely. We conclude that TxA 2 is involved in allograft arteriosclerosis, although the impact is relatively smalL (Arteriosclerosis and Thrombosis 1992;12:1380-1386 
basic feature in all allografts undergoing chronic rejection is persistent perivascular inflamma-L tion and allograft arteriosclerosis. 12 In contrast to classical atherosclerosis, which is usually focal and asymmetric, allograft arteriosclerosis is concentric and generalized. Allograft arteriosclerosis particularly affects the first-and second-order intragraft arteries to the level of the arterioles. 2 The regulation of arterial smooth muscle cell proliferation in chronically rejecting allografts is probably complex. Cytokines produced by inflammatory cells as well as growth factors produced by both these and graft parenchymal cells may be involved.
Several lines of evidence indicate that arachidonic acid metabolites also participate in the regulation of smooth muscle cell proliferation in rejecting allografts.
In clinical studies patients who experience chronic allograft rejection may have increased levels of thromboxanes in their blood and urine while the levels of prostaglandins and prostacyclin are the same or lower than in control subjects. 3 Prostaglandins are known to inhibit the proliferation of smooth muscle cells in vitro, 4 -5 whereas the leukotrienes LTB 4 , LTQ, and LTD 4 initiate DNA synthesis of growth-arrested arterial smooth muscle cells. 6 We have recently developed an animal model for allograft arteriosclerosis. 7 In short, aortic allografts are transplanted without immunosuppression between histoincompatible rat strains. After a short, spontaneously reversible acute episode of rejection, these allografts develop vascular wall changes that are virtually identical to those observed in human tissue transplants undergoing chronic rejection.
In this communication we demonstrate that aortic allografts undergoing chronic rejection exhibit an increased synthesis of thromboxane B2 (TxB^) but only a small increase in the synthesis of 6-ketoprostaglandin F l a (6-keto-PGF lo ) and no increase in LTB 4 . Blocking of the thromboxane pathway by a specific inhibitor of the TxA 2 receptor, although inhibitory to inflammatory cell proliferation, only temporarily attenuates the development of arteriosclerotic alterations in these transplants.
Methods

Experimental Animals
Rat strains WF (AG-B2, RTT) and DA (AG-B4, RT1") were used for transplantation. All animals were purchased from the Zentralinstitut fur Versuchstierzucht GmbH, Hannover, FRG. Male rats weighing 200-300 g and 1-3 months of age were used as donors and recipients. 
Aortic Transplantations
A segment of the descending thoracic aorta (approximately 3 cm) was excised, perfused with saline, and used as a transplant. 7 The experimental animals were anesthetized with intraperitoneal chloral hydrate (6 ml/kg body wt). The graft was perfused and transplanted into a heterotopic position below the renal arteries and above the bifurcation, thereby forming a "loop" in the abdominal cavity. This modification of the original technique allowed us to obtain more material for both histological and biochemical determinations. The histological results did not differ from those originally reported. 7 The cranial suture line was completed as close to the renal arteries as technically possible to minimize the difference in diameter. An end-to-end anastomosis was performed by using a 9-0 continuous nylon suture. The DA-to-WF-strain combination was used for the allografts. Syngeneic control grafts were made from the DA to the DA strain. The grafts were removed at 10 and 20 days and at 1, 3, and 6 months after transplantation and processed for histology, autoradiography, frozen-section immunohistochemistry, and biochemical determinations. Both in situ fixation, via infusion of 10% neutral formaldehyde to the left atrium before the anesthetized animal was killed, and regular fixation were employed with similar results. Specimens for immunohistochemistry were immersed in TissueTek, Miles, Elkhart, Ind., and snap-frozen.
Medication
GR32191B, which is a potent and specific TxA 2 receptor antagonist, 8 was a gift from the Glaxo Group Research Ltd., Greenford, UK The drug was dissolved in water and administrated orally (forced administration) at the rate of 1.0 mg • kg" 1 • day" 1 until the end of the experiment. This dose is approximately 10 times higher than the dose that inhibits accumulation of platelets onto denuded guinea pig carotid arteries.
Histological Specimens and Staining
For evaluation of morphological changes, paraffin sections were stained with Mayer's hematoxylin and eosin, and orcein was used for elastic fibers. Longitudinal sections were also prepared, for which the vessel wall on both the graft and host sides of the suture line could be observed, as well as cross sections for quantification of circular changes in the graft. Quantitative histology (morphometry) was always done from the middle (one third) section of the transplant. Aortas from normal nontransplanted rats and the thoracic aorta of the recipient rat were used as controls.
Immunohistochemistry
For immunohistochemistry, 3-4-/xm-thick frozen sections were stained by the immunoperoxidase technique by using monoclonal anti-rat antibodies to leukocyte common antigen (LCA) and a-smooth muscle actin. Anti-LCA (OX-1) antibody was obtained from Sera Lab, Sussex, UK, and anti-smooth muscle actin antibody was from Bio-Makor, Rehovot, Israel. The cryosections were stained by the two-layer indirect immunoperoxidase technique described in detail elsewhere. 9 Briefly, the sections were incubated with appropriately diluted monoclonal antibody (usually 1:20), washed, and consecutively incubated with peroxidaseconjugated rabbit anti-mouse immunoglobulin and goat anti-rabbit immunoglobulin (Dako Immunoglobulins a/s, Glostrup, Denmark), followed by treatment with a substrate solution containing the chromogen 3-amino-9-ethylcarbazole. Hydrogen peroxide was added to the 3-amino-9-ethylcarbazole solution immediately before use. The samples were counterstained with Mayer's hemalum solution and mounted.
Quantification of Histology in Rat Aortic Transplants
The morphological changes were quantified according to standard morphometric principles 10 and expressed as point score units (PSUs), i.e., the mean number of points falling over a given anatomic area defined by straight cross-sectional lines and a 0.02-mm grid. The following variables were evaluated: the number of nuclei and the thicknesses of different layers of the aorta, i.e., adventitia, media, and intima, separated pairwise from each other by external and internal elastic laminae, respectively. A minimum of five technically successful transplantations were made for each time point unless otherwise noted, and their means (±SEM) were used as final scores.
Autoradiography
Some of the rats received 250 fid of tritium-labeled thymidine ( 3 H-TdR, NEN, Boston, Mass.) by intravenous injection 3 hours before they were killed. Histological specimens were processed from paraffin sections, emulsion autoradiography (Ilford L.4, Ilford, Mobberley, UK) was performed, and the labeling of the nuclei in the transplanted aortic wall was compared with the labeling index in the recipient aorta. On some occasions autoradiography was performed on immunohistochemically stained slides to identify the type of 3 H-TdRlabeled cells.
Eicosanoid Measurements From Rat Aortas
Aortic allografts and thoracic and abdominal aortas of the recipient or of a normal rat were removed and sliced. Aortas were first incubated for 30 minutes in an ice bath with 0.1 M sodium phosphate buffer, pH 7,4, in 0.9% NaCl supplemented with 1% bovine serum albumin, 200 nM calcium ionophore (Siznen), and 0.1% NaN 3 and thereafter for another 30 minutes at 37°C in the same buffer (1-3 ml). Exclusion of NaN 3 and/or calcium ionophore from the incubation medium (which was present in the preliminary experiments in Table 1 ) did not affect the eicosanoid determinations. The incubation was stopped by reimmersing the aortas in the ice bath. Liquids were collected from the incubation tubes for radioimmunoassay, and the aortas were dried overnight at 37°C and weighed. Commercially available radioimmunoassay kits (Amersham, Amersham, UK) for the stable end products, 6-keto-PGF la for prostacyclin, TxBi for TxA 2 , and LTB 4 , were employed. Normal nontransplanted aortas were used as controls. The results were expressed as nanograms or picograms per milligram of aorta (dry weight).
Results
Synthesis of Major Eicosanoids by the Arterial Wall
DA rat thoracic aortas were transplanted to WF or DA recipients and removed 1 month after transplantation. The middle part (one third) of the transplant was cut into slices and incubated in serum-free medium in vitro, and the incubation medium was investigated for the presence of 6-keto-PGF la , TxBj, and LTB 4 by using specific radioimmunoassays. As shown in Table 1 , the synthesis of TXB2 increased significantly from about 300 pg/mg to about 3,500 pg/mg dry wt in the allografts; there was also a modest increase in the synthesis of TxBj to approximately 850 pg/mg in the syngeneic grafts. In contrast, there was no significant increase in the synthesis of 6-keto-PGFi a in the allografts or in syngeneic grafts when compared with nontransplanted aortas (not shown) or to the recipients' own aortas; neither was there any measurable increase in the synthesis of LTB 4 .
Time Profile of Thromboxane Response
Another set of experiments was performed to investigate the time dependence of the thromboxane response by comparing allografts to syngeneic grafts up to 5-9 months after transplantation. As shown in Figure 1 , at 1 week after transplantation, increased amounts of TXB2 were measured from both the allografts and the syngeneic grafts. Thereafter, the synthesis of TxBj rapidly declined to a level of approximately 500-1,000 pg/mg dry wt in syngeneic grafts but remained at a high level of approximately 5,000-6,000 pg/mg dry wt in allografts up to the end of the observation period of 5 months.
Synthesis of' 6-Keto-PGF'," and TxB 2 by Different Layers of the Vascular Wall
For some reason that we do not know, the cohesion between the newly formed intima and media was relatively weak in advanced arteriosclerosis. This made it possible for us to dissect these two components by standard microdissection techniques (Figure 2 ), which thereby permitted the analysis of eicosanoids separately from the intima and (media plus) adventitia.
In the third experiment, therefore, we investigated the origin of 6-keto-PGF,,, and TXB2 in regard to the major components of the aortic wall, i.e., the intima and the (media plus) adventitia. The wall components of the aortic allografts were microdissected along the internal elastic lamina (Figure 2) , and the resulting two components were investigated separately.
As shown in Table 2 , both vascular wall components synthesized prostanoids. However, more 6-keto-PGF lCT was synthesized in the intima, whereas more of the TxBj synthesis occurred in the outer layers of the aortic wall, i.e., in the component consisting of media and inflammatory adventitia.
Proliferation of Inflammatory and Smooth Muscle Cells in the Vascular Wall and Effect of TxA 2 Antagonist GR32191B on the Proliferate Response
Aortic allografts were performed from the DA to the WF rat strain or, for comparison, from the DA to the DA strain. One group of allograft recipients received 1 mg • kg" 1 • day" 1 GR32191B. This dose is 10 times more than the minimum dose that produces maximal inhibition of platelet deposition onto denuded guinea pig carotid arteries. The allograft recipients received an intravenous bolus of 250 /iCi 3 H-TdR 3 hours before they were killed, and autoradiograms were made from the paraffin sections.
In untreated allograft recipients there was a rapid increase in the number of 3 H-TdR-incorporating cells in the adventitia (Figure 3 ). Combined autoradiography and staining for anti-a-smooth muscle actin and/or anti-LCA demonstrated that most of the labeled cells in the adventitia were LCA-positive inflammatory white cells, but occasional labeled cells expressing a-smooth muscle actin were also found (not shown). The remaining labeled cells were double-antibody-negative. A high level of white cell proliferation in the adventitia lasted for 4 months after transplantation, after which time it declined. Only occasional 3 H-TdR-incorporating cells 
FIGURE 3. Semilogplots showing number of tritiated-thymidine-incorporating cells per cross section in the adventitia (panel a), media (panel b), and intima (panel c) ofallografts (•), syngeneic grafts (o), and GR22191B-treated allografts (•). Values are mean±SEM of at least three determinations for each point, with SEM shown as vertical bars.
were seen in the adventitia of syngeneic control rats. Administration of 1 mg • kg" 1 • day" 1 GR32191B significantly reduced the proliferative response of inflammatory white cells in the allograft adventitia from approximately 200 cells to 50-130 cells per cross section but did not block it entirely.
There was also a rapid increase in the number of 3 H-TdR-incorporating cells in the media of the allografts, lasting 1-3 months after transplantation, after which time the proliferative response in the media declined ( Figure 3 
FIGURE 4. Semilog plots showing morphometric quantification in "point score units" (psu) of the nuclei in the adventitia (panel a), media (panel b), and intima (panel c) and the thickness of the intima (panel d) in DA-to-WF allografts (•), DA-to-DA syngeneic grafts (o), and DA-to-WF aUografts treated with GR32191B (•) (mean±SEM). Closed box and shading indicate normal DA control aortas (mean±SD). At least five determinations were made for each time point, with SEM indicated by vertical bars. The difference in the number ofintimal nuclei and intimal thickness between untreated and GR32191B-treated aUografts at 1 month after transplantation is significant (p<0.01). X axis is time in months.
controls. Administration of GR32191B did not reduce the proliferative response of smooth muscle cells in the media. The first 3 H-TdR-incorporating cells were seen in the allograft intima at 0.5-1 month after transplantation (Figure 3) , and contrary to the results cited above, the cell proliferation in the intima did not decline but continued at a reasonable level until the end of the observation period of 5 months. Counterstaining with monoclonal antibodies demonstrated that most of the 3 H-TdR-incorporating cells in the intima were again smooth muscle cells (not shown). In addition there were some double-antibody-negative cells, but no LCA-positive white cells incorporating 3 H-TdR were observed in the intima. Practically no smooth muscle cell proliferation was seen in the intima of syngeneic controls. Administration of GR32191B did not reduce the number of 3 H-TdR-incorporating smooth muscle cells in the alJograft intima.
Quantification of Vascular Wall Changes in Allografts, Syngeneic Grafts, and Allografts Treated With GR32191B
Aortic allografts were exchanged between the same strain combinations as above, and one group of the allograft recipients received 1 mg • kg" 1 • day" 1 GR32191B. The drug-treated animals were killed 1-4 months postoperativery, and the control rats were killed at 5, 6, and 12 months. Morphometric quantification was done for the inflammatory cell nuclei in the adventitia, for the smooth muscle cell nuclei in the media, and for the nuclear content and thickness of the intima by using paraffin sections from the middle third of the transplant As shown in Figure 4 , there was a rapid increase in the nuclear density in the adventitia of DA-to-WF allografts. Staining with anti-LCA anti-a-smooth muscle cell actin antibodies previously demonstrated that most of these were nuclei of LGA-positive inflammatory cells. 7 The inflammation peaked at the second month after transplantation and gradually declined thereafter (Figure 4) . In syngeneic control rats, only a modest adventitial inflammatory response was observed. Administration of GR32191B to the allograft recipients did not reduce the intensity of the inflammation in the allograft adventitia ( Figure 4) .
The nuclear density of the media rapidly declined in the allografts (Figure 4) , indicating medial necrosis. In syngeneic grafts, the smooth muscle cell nuclei were preserved in the media. Administration of GR32191B to the allograft recipients did not delay the loss of smooth muscle cells from the media, i.e., medial necrosis, and was definitely unable to inhibit it ( Figure 4) .
The nuclear density in the allograft intima rapidly increased. As previously shown, 7 most of the cells invading the subendothelial space are a-actin-containing smooth muscle cells. No such influx of smooth muscle cells into the intima was observed in syngeneic control rats (Figure 4) . At 1 month after transplanta-tion, significantly (/?<0.01) fewer smooth muscle cell nuclei were recorded in the intima of GR32191B-treated allografts (1.2±0.2 PSUs) compared with untreated allografts (2.3+0.6 PSUs); however, the difference disappeared at 2-3 months after transplantation (Figure 4) . This was also the case when the intimal response was quantified as intimal thickness: there was a rapid increase in the cross-sectional thickness of the intima in allografts, which was not observed in syngeneic control rats (Figure 4) . Administration of GR32191B delayed the intimal response by approximately 1 month but was unable to inhibit it indefinitely.
Discussion
Disregarding the organ-specific manifestations in the kidney, 11 ' 12 liver, 13 and heart transplants, 14 the common denominator of chronic rejection in all of these allografts is persistent periarterial inflammation and allograft arteriosclerosis.
We have previously demonstrated that with longer observation times, histoincompatible rat aortic allografts develop vascular wall changes that are comparable with those seen in chronic rejection. 7 Persistent perivascular inflammation, gradual loss of smooth muscle cells in the media, fragmentation of the internal elastic lamina, and appearance of proliferating smooth muscle cells in the intima, all of which were observed in these experimental allografts, are virtually identical with the vascular changes observed in human heart and kidney allografts during chronic rejection.
To understand the molecular mechanism in allograft arteriosclerosis, it is, therefore, crucial to understand how the perivascular inflammation regulates the smooth muscle cell proliferation in the allograft vascular wall. Here the picture becomes more complex. The cells in both the inflammatory infiltrate (including platelets) 15 " 17 and the vascular wall itself are able to produce multifunctional cytokines and growth factors that can potentially induce these morphological alterations. 15 In addition to lymphokines and growth factors, another group of molecules that can potentially modify the arteriosclerotic process is the lipid mediators of inflammation. Prostaglandins have cytoprotective effects and inhibit the proliferation of smooth muscle cells in vitro, 4 -5 whereas leukotrienes may initiate DNA synthesis of subcultured rat arterial smooth muscle cells. 6 -18 Treatment of these cells with cyclooxygenase inhibitors, acetosalicylic acid, or indomethacin blocks the induction of DNA synthesis, suggesting that the effect is mediated by a cyclooxygenase product. 6 Thus, one potential candidate for this effector molecule would be TxA 2 . Thromboxane has not yet been considered a vascular smooth muscle cell growth-promoting substance per se. 18 On the other hand, thromboxanes cause local platelet activation and vasoconstriction, and they are also considered to be "pro-inflammatory" cytokines.
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This study demonstrates a series of findings that are compatible with this suggestion. When the release of the major eicosanoid end products, i.e., 6-keto-PGF la , TxBj, and LTB 4 , was quantified after short-term incubation of aortic slices in vitro, there was a significant increase in the production of TxB2 in the allografts but only a small increase in the production of 6-keto-PGF lo and no increase in LTB 4 . The increase in TxB2 production in the allografts prevailed over that in the syngeneic grafts throughout the observation time of 5-9 months. When the major aortic wall components were analyzed separately, it appeared that the increased synthesis of TxB2 was particularly due to the cells present in the outer layers of the aorta, most likely the inflammatory cell population in the adventitia, including lymphocytes and macrophages. 7 In contrast, the synthesis of 6-keto-PGF la was particularly due to the cells present in the intima, most likely the endothelial cells of the inner intimal lining and the smooth muscle cells. 18 Observations of an increased synthesis of TxB2 in our aortic allografts but hardly any increase of 6-keto-PGF la and no measurable increase of LTB 4 are also concordant with previous findings in humans. Clinical studies have shown that in chronic rejection there is an increase in the level of thromboxane, whereas the levels of prostaglandins and prostacyclin are lower than in control subjects. 3 This study extends these clinical findings and demonstrates that thromboxane, or at least a substantial part of it, derives from the graft itself, particularly from the inflammatory component.
The "anti-inflammatory" effect of the blocking of the TxA 2 cascade with a receptor inhibitor was also observed in our study. Although the administration of GR32191B did not inhibit the accumulation of inflammatory cells into the allograft, it reduced the proliferation of the inflammatory cells by approximately 30%. However, because the proliferate responses of smooth muscle cells in the media and the intima were not reduced by GR32191B, it is impossible to evaluate whether the proliferation of smooth muscle cells in the allograft is indeed under the control of inflammatory leukocytes. With respect to the inability of the receptor blocker to inhibit the proliferation of smooth muscle cells, we have assumed that the adenylate cyclasecoupled receptor protein present in platelets would also be present in smooth muscle cells. This may not be the case. The possibility that different thromboxane receptors are present in inflammatory cells compared with platelets and/or that they are not equally blocked by this drug at the concentration used 20 may, however, be ruled out.
Another interesting observation also derives from the autoradiography data. In untreated allografts, the proliferation of smooth muscle cells in the media declined concomitantly with the proliferation of inflammatory cells in the adventitia. However, in the intima the smooth muscle cells continued to proliferate, though at a lower level. This might indicate that although the proliferative response of smooth muscle cells may initially be under the control of the inflammatory stimulus, the response may later become autonomous of this. Some studies have also claimed a benefit from the use of antiplatelet agents, prostacyclin agonists, or thromboxane antagonists 3 -21 in chronic rejection in humans; however, these findings have not been confirmed in experimental models. 22 -23 This is also the case here: administration of a specific TXB2 receptor inhibitor at a dose 10 times higher than that required to inhibit the adhesion of platelets to the denuded guinea pig vascular wall only slightly delayed the arteriosclerotic process.
Taken together, our findings indicate that the lipid mediators of inflammation, particularly TxA 2 , are involved in the arteriosclerotic process of chronic rejec-tion in organ allografts. At present we consider that the lipid inflammatory mediators of inflammation play an intermediatory role, which may be bypassed by some other currently unidentified mechanisms.
